Who are the top shareholders of the Medicamen?

The top shareholders of Medicamen include Bal Kishan Gupta with 52.16%, followed by public shareholder Shivani Chopra at 5.13%. Individual investors collectively hold 28.79%, and there is one Foreign Institutional Investor with a 0.07% stake.

The top shareholders of Medicamen include the promoters, with Bal Kishan Gupta holding the highest share at 52.16%. There are no pledged promoter holdings, and the company has one Foreign Institutional Investor (FII) holding 0.07%. The highest public shareholder is Shivani Chopra, who owns 5.13%. Additionally, individual investors collectively hold 28.79% of the shares.

When is the next results date for Medicamen?

No Upcoming Board Meetings

Has Medicamen declared dividend?

No Dividend History Available

What is the technical trend for Medicamen?

As of June 3, 2025, Medicamen's technical trend is mildly bullish, supported by the weekly MACD, Bollinger Bands, and Dow Theory, despite some caution from daily moving averages and a bearish weekly KST.

As of 3 June 2025, the technical trend for Medicamen has changed from sideways to mildly bullish. The weekly MACD indicates a mildly bullish stance, while the Bollinger Bands also reflect a bullish condition. The Dow Theory supports this with a mildly bullish signal on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, which introduces some caution. The weekly KST is bearish, but the OBV shows a mildly bullish trend. Overall, the current technical stance is mildly bullish, driven primarily by the weekly MACD, Bollinger Bands, and Dow Theory indicators.

Who are the peers of the Medicamen Organ.?

Medicamen Organ.'s peers include JFL Life, Mono Pharmacare, Roopa Industries, and others. Medicamen has excellent management and growth but a below-average capital structure, with a 1-year return of -63.92%, better than JFL Life's -71.12% but worse than Mono Pharmacare's -34.38%.

Peers: The peers of Medicamen Organ. are JFL Life, Mono Pharmacare, Roopa Industries, Chandra Bhagat, Kabra Drugs, ANG Lifesciences, Sandu Pharma., Veerhealth Care, and Transchem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medicamen Organ., while Average management risk is found at JFL Life and Transchem. Below Average management risk is noted at Mono Pharmacare, Roopa Industries, Chandra Bhagat, ANG Lifesciences, Sandu Pharma., and Veerhealth Care, and the rest. Growth is Excellent at Medicamen Organ., Good at JFL Life, Mono Pharmacare, and Roopa Industries, while Below Average growth is seen at Chandra Bhagat, ANG Lifesciences, Sandu Pharma., and Veerhealth Care, and the rest. Capital Structure is Below Average at Medicamen Organ., Mono Pharmacare, Roopa Industries, Chandra Bhagat, ANG Lifesciences, and Transchem, while Average is noted at JFL Life, and Good at Sandu Pharma. and Veerhealth Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Mono Pharmacare at -34.38%, while the lowest is JFL Life at -71.12%. Medicamen Organ.'s 1-year return of -63.92% is better than JFL Life's but worse than Mono Pharmacare's. Additionally, several peers, including JFL Life, Medicamen Organ., Mono Pharmacare, and others, have negative six-month returns.

What does Medicamen Organ. do?

Medicamen Organics Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, originally incorporated as Panchdeep Pharmaceuticals in 1995. It has a market cap of INR 44 Cr, with a P/E ratio of 14.00 and a return on equity of 21.54%.

Overview: <BR>Medicamen Organics Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>Medicamen Organics Limited was incorporated on March 15, 1995, originally as Panchdeep Pharmaceuticals Limited. The company changed its name to Medicamen Organics Limited, receiving a fresh Certificate of Incorporation on November 14, 1995. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 44 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.80 <BR>Return on Equity: 21.54% <BR>Price-to-Book: 2.91 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Medicamen Organ.?

As of 24th July, Medicamen Organics Ltd has a market capitalization of 46.00 Cr, classifying it as a Micro Cap company. Shareholder's Funds are valued at 15.18 Cr, and Total Assets amount to 38.58 Cr, but recent quarterly performance data is unavailable.

As of 24th July, Medicamen Organics Ltd has a market capitalization of 46.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent quarterly performance data is not available, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>In the balance sheet snapshot for the reporting period of March 2024, Shareholder's Funds are valued at 15.18 Cr, and Total Assets amount to 38.58 Cr.

How has been the historical performance of Medicamen Organ.?

Medicamen Organ experienced significant financial growth from March 2024 to March 2025, with net sales rising to 38.19 Cr and profit after tax increasing to 4.05 Cr. Key metrics such as operating profit and earnings per share also improved, indicating strong overall performance.

Answer:<BR>The historical performance of Medicamen Organ shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Medicamen Organ's net sales increased from 25.27 Cr in March 2024 to 38.19 Cr in March 2025, contributing to a total operating income rise to 38.19 Cr from 25.27 Cr. The company's total expenditure also grew, reaching 31.60 Cr from 20.53 Cr, primarily driven by higher raw material costs, which rose to 22.25 Cr from 14.40 Cr. Operating profit (PBDIT) improved to 6.69 Cr from 5.81 Cr, although the operating profit margin decreased slightly to 17.26% from 18.76%. Profit before tax increased to 5.43 Cr from 4.44 Cr, leading to a profit after tax of 4.05 Cr, up from 2.62 Cr. The company's earnings per share rose to 3.46 from 3.05, while the book value per share increased to 25.11 from 17.74. On the balance sheet, total assets grew to 59.21 Cr from 38.44 Cr, with total liabilities also increasing to 59.21 Cr from 38.44 Cr. Cash flow from financing activities saw a notable increase to 10.00 Cr from 4.00 Cr, resulting in a net cash inflow of 3.00 Cr compared to no inflow in the previous year. Overall, Medicamen Organ demonstrated a strong financial performance with growth across key metrics.

Is Medicamen Organ. overvalued or undervalued?

As of December 3, 2025, Medicamen Organ. is considered undervalued with a PE ratio of 9.64 and attractive valuation metrics compared to peers like Sun Pharma and Divi's Lab, making it a compelling investment opportunity despite a challenging year.

As of 3 December 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade, indicating a shift in its market perception. The company is currently considered undervalued, with a PE ratio of 9.64, an EV to EBIT of 9.14, and an EV to EBITDA of 7.92, which are significantly lower than its peers. For instance, Sun Pharma. has a PE ratio of 37.51 and an EV to EBITDA of 24.8, while Divi's Lab. shows a PE of 68.92 and an EV to EBITDA of 51.79, highlighting the relative attractiveness of Medicamen's valuation.<BR><BR>In comparison to its peers, Medicamen Organ. stands out with a PEG ratio of 0.00, suggesting that it is priced favorably relative to its growth prospects. Other attractive peers include Cipla and Dr. Reddy's Labs, with PE ratios of 22.39 and 18.52, respectively. Despite a challenging year with a YTD return of -50%, the valuation metrics suggest that Medicamen Organ. presents a compelling investment opportunity in the pharmaceuticals and biotechnology sector.

Why is Medicamen Organ. falling/rising?

As of 20-Dec, Medicamen Organics Ltd's stock price is rising to 25.20, up 5.0%, but it has a year-to-date decline of 53.25%. Despite today's increase, the stock remains below several key moving averages and shows reduced investor participation, indicating potential long-term challenges.

As of 20-Dec, Medicamen Organics Ltd's stock price is rising, currently at 25.20, which reflects an increase of 1.2 or 5.0%. This rise is notable as it outperformed the sector by 4.25% today. Despite this positive movement, the stock has shown a negative performance over the longer term, with a year-to-date decline of 53.25% and a one-year decline of 55.24%. <BR><BR>Additionally, while the stock is currently higher than its 5-day moving averages, it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages, indicating that it may still be under pressure in the longer term. Furthermore, there has been a significant drop in investor participation, with delivery volume falling by 47.37% against the 5-day average, which could suggest a lack of sustained interest from investors. <BR><BR>Overall, while the stock is experiencing a rise in price today, the broader context shows significant challenges that could affect its future performance.

Which are the latest news on Medicamen Organ.?